Principal Scientist - Global Research

CellCarta establishes strategic partnership with Waters to advance companion diagnostics development. Oct 05, 2026, 09:15 ET Collaboration combines CellCarta's global clinical trial testing capabilities with Waters' standardized flow cytometry platforms and expertise MONTREAL, Oct. 5, 2026 /PRNewswire/ - CellCarta, a leading global CRO laboratory to the biopharmaceutical industry, today announced a strategic partnership with Waters Corporation, a global leader in life sciences and diagnostics, creating a framework to jointly pursue companion diagnostic (CDx) and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs. For CDx opportunities, the partnership aims to provide sponsors with a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. The complementary expertise of CellCarta and Waters spans assay innovation, development, validation, and global implementation. Waters provides underlying technology capabilities, including instrumentation, reagents, standardized panels, assay development, software analysis, and, where appropriate, custom reagent and IVD commercialization. CellCarta leverages its extensive biomarker, translational research, and clinical development expertise to integrate and deploy the assay across its global CDx Lab Network, supporting Phase I-III clinical trial testing, generation of analytical and clinical evidence, regulatory and logistics support, and commercial laboratory services. Together, the companies aim to deliver standardized and globally scalable solutions for precision medicine. The existing platform alignment between CellCarta's CAP-accredited laboratory's capabilities in Jining, China and BD flow cytometry platforms create a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs, as well as China-based biopharmaceutical companies preparing to expand their therapies and diagnostic strategies globally. "For our biopharmaceutical sponsors, the business value of this partnership is clear: a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization," said Todd Chermak, President of CellCarta. "By combining CellCarta's end-to-end laboratory capabilities with Waters' diagnostic and CDx development expertise, and flow cytometry platforms, we can help sponsors reduce complexity, preserve program continuity and make earlier, more informed decisions about how to scale their programs. We are already engaging pharmaceutical and biotechnology companies on near-term opportunities where this combined model can make a meaningful difference." "In particular for China, this partnership has the potential to help sponsors pursue more consistent China-to-global and global-to-China pathways while accounting for cross-border, regulatory, and operational requirements," said Christopher Ung, Chief Scientific Business Officer and Head of China Strategy for CellCarta. "Together, we can connect patient selection with treatment-response assessment - and make China part of that strategy from the beginning." "Next-generation flow cytometry is expanding what laboratories can see by combining highly sensitive rare-cell analysis with greater standardization across the entire workflow," said Brent Gaylord, VP/GM Reagents, Waters Biosciences, Waters Corporation. "By combining CellCarta's contract research organization expertise with Waters' clinical assay development expertise and integrated instruments, reagents, and informatics, this collaboration is designed to help biopharmaceutical sponsors translate high-value cellular insights into clinical assays that can be consistently deployed across programs and geographies." About CellCarta CellCarta is a leading global CRO laboratory to the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, the United States, Belgium, Australia and China, CellCarta provides a wide range of biomarker testing services and customized solutions to world-renowned pharmaceutical companies. By integrating analytical platforms in immunology, histopathology, proteomics and genomics, along with sample management and logistics services, CellCarta supports the entire drug-development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with CellCarta on LinkedIn and X. Media Contacts CellCarta Stéphanie Bussières-Marmen, PhD Director, Global Marketing [email protected] Melanie Williams Senior Marketing Communications Specialist, Supreme Optimization [email protected] SOURCE CellCarta

Waters Corporation (NYSE:WAT) receives consensus rating of "Moderate Buy" from brokerages. September 29, 2026 Key points. * Analysts rate Waters "Moderate Buy": Of 20 analysts, 11 recommend buying, three strongly recommend buying and six rate it a hold. The average 12-month price target is $434.60. * Shares trade near their 52-week high: Waters opened at $443.80, up 2.4%, with a market capitalization of approximately $43.6 billion. * Quarterly results exceeded expectations: The company reported adjusted earnings of $3.05 per share versus the $3.01 consensus estimate and revenue of $1.65 billion, up 113.3% year over year. Analysts expect full-year 2026 earnings of about $14.56 per share. * Five stocks to consider instead of Waters. Shares of Waters Corporation (NYSE:WAT - Get Free Report) have received an average recommendation of "Moderate Buy" from the twenty analysts that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $434.60. Several equities analysts have recently issued reports on WAT shares. Morgan Stanley set a $430.00 price objective on Waters in a research note on Wednesday, August 5th. UBS Group upgraded shares of Waters from a "neutral" rating to a "buy" rating and upped their target price for the stock from $375.00 to $490.00 in a research note on Wednesday, September 9th. Wells Fargo & Company raised their target price on shares of Waters from $370.00 to $400.00 and gave the company an "equal weight" rating in a report on Wednesday, August 5th. Evercore reiterated an "outperform" rating and issued a $420.00 price target on shares of Waters in a research note on Wednesday, August 5th. Finally, Bank of America boosted their price target on shares of Waters from $370.00 to $400.00 and gave the stock a "neutral" rating in a report on Tuesday, June 2nd. Insider buying and selling. In other news, Director Christopher Kuebler sold 3,626 shares of Waters stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the sale, the director owned 17,808 shares in the company, valued at approximately $7,086,515.52. The trade was a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.31% of the stock is owned by company insiders. Institutional inflows and outflows. Institutional investors have recently added to or reduced their stakes in the company. PenderFund Capital Management Ltd. purchased a new position in shares of Waters in the 2nd quarter valued at about $28,000. First Bancorp Inc ME purchased a new stake in Waters during the second quarter worth about $30,000. Caitlin John LLC boosted its holdings in Waters by 43.9% during the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier's stock worth $31,000 after buying an additional 25 shares in the last quarter. SHP Wealth Management acquired a new position in Waters during the fourth quarter worth about $32,000. Finally, Anchor Investment Management LLC acquired a new position in Waters during the first quarter worth about $27,000. Institutional investors and hedge funds own 94.01% of the company's stock. Waters trading up 2.4%. WAT opened at $443.80 on Tuesday. Waters has a 52 week low of $282.77 and a 52 week high of $445.48. The company has a quick ratio of 1.29, a current ratio of 1.86 and a debt-to-equity ratio of 0.32. The business has a fifty day simple moving average of $406.32 and a 200-day simple moving average of $363.03. The firm has a market cap of $43.60 billion, a P/E ratio of 110.67, a P/E/G ratio of 2.52 and a beta of 1.19. Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, beating analysts' consensus estimates of $3.01 by $0.04. The firm had revenue of $1.65 billion during the quarter, compared to analysts' expectations of $1.62 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The business's quarterly revenue was up 113.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.95 earnings per share. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, equities analysts expect that Waters will post 14.56 earnings per share for the current year. Waters company profile. Waters Corporation NYSE: WAT develops and manufactures analytical workflow technologies used to measure, characterize and manage chemical and biological substances. Its customers include pharmaceutical and biopharmaceutical companies, industrial organizations, academic institutions and government laboratories. The company's portfolio includes liquid chromatography, mass spectrometry and thermal analysis instruments, along with chromatography columns, consumables, laboratory software and services. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Waters, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list. While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list. Continue following MarketBeat